Gerresheimer Increases Revenues by 8.8% and Successfully Integrates Sensile Medical

Düsseldorf, Germany (ots/PRNewswire) -

- Revenues at constant exchange rates up 8.8% in third quarter of
2018 to EUR 364.4m
- Adjusted EBITDA at constant exchange rates-excluding Sensile
Medical and negative effects relating to the exemption from
electricity network charges-increased by EUR 1.3m in third quarter
to EUR 79.5m
- Integration of Sensile Medical proceeding to plan; first product
gains CE declaration of conformity
- Outlook: - Revenue guidance for 2018, excluding Sensile Medical,
as before
between approximately EUR 1.38bn and EUR 1.4bn
- Guidance for adjusted EBITDA at constant exchange rates,
excluding
Sensile Medical, in a range from approximately EUR 305m to EUR
315m, tending toward around EUR 305m according to implementation
of development work for large projects
- Initial, preliminary indications with regard to long-term Group
performance provided in second quarter report continue to apply

Gerresheimer AG significantly increased revenues at constant
exchange rates in the third quarter of the financial year 2018 (June
1 to August 31, 2018). Organic growth was likewise substantial, as
was growth in the first three quarters. "Our business is pulling
ahead as expected-the third quarter went well. We are consequently
confirming our revenue guidance for this year. The integration of
Sensile Medical, the technology group acquired in July, is also
proceeding fully to plan. Its first product has gained European
certification and is now being brought to market by the pharma
company concerned," said Rainer Beaujean, Speaker of the Management
Board and CFO.

The Gerresheimer Group increased revenues at constant exchange
rates by 8.8% in the third quarter of 2018, from EUR 335.0m in the
prior-year quarter to EUR 364.4m. This includes EUR 3.5m from Sensile
Medical, which was acquired in July 2018. On an organic basis-meaning
adjusted for exchange rate effects and Sensile Medical-revenues went
up by 7.8% relative to the prior-year quarter. In the first nine
months of 2018, revenues at constant exchange rates rose by 3.9%. The
third quarter brought revenue growth in plastic pharmaceutical
packaging in Europe and notably also in India and South America.
Demand for plastic vials for prescription drugs in the USA was
stable. In the prefillable syringes business, demand generally
remains very good despite a slight drop in customer call-off orders
during the third quarter. Medical plastic systems continue to be a
revenue growth driver, especially due to the inhaler project in the
USA. However, there was a decrease in demand from a number of pharma
customers for whom Gerresheimer is the sole supplier. The moulded
glass business showed strong positive growth rates, most notably in
sales of cosmetic glass. With products such as injection vials,
ampoules and cartridges, the recovery in the US business continued
and there was also growth in Europe. Revenues at constant exchange
rates in the new Advanced Technologies Division, which covers Sensile
Medical, came to EUR 3.5m in the third quarter. In September, a
wearable micro pump from Sensile Medical received CE certification
for the European market. Custom-designed for the treatment of
Parkinson's disease, the pump can now be brought to market by the
pharma company concerned.

Adjusted EBITDA at constant exchange rates decreased from EUR
78.2m in the prior-year quarter to EUR 76.1m. Two negative effects
have to be taken into account here: An expense of EUR 1.4m was
recognized in the third quarter due to the European Commission
decision on the exemption from network charges granted to large
electricity-consuming enterprises in 2012 and 2013. Furthermore,
adjusted EBITDA at constant exchange rates for the Advanced
Technologies Division is a negative EUR 2.0m. Without these two
effects, adjusted EBITDA at constant exchange rates would have
totaled EUR 79.5m, EUR 1.3m higher than in the prior-year quarter.
The adjusted EBITDA margin in the third quarter of 2018 was 20.9%.
Excluding the expense relating to the exemption for electricity
network charges and excluding the new Advanced Technologies Division,
the adjusted EBITDA margin came to 22.0%, which, as expected, is
below the 23.4% prior-year figure.

Adjusted net income after non-controlling interests came to EUR
32.0m in the third quarter, compared with EUR 31.3m in the prior-year
quarter. The adjusted earnings per share after non-controlling
interests came to EUR 1.02 in the third quarter, compared with EUR
1.00 a year earlier.

Net financial debt increased by EUR 193.1m to EUR 905.8m as of
August 31, 2018, primarily due to payment of the first installment of
the purchase price for Sensile Medical. Calculated as the ratio of
net financial debt to adjusted EBITDA over the last twelve months,
adjusted EBITDA leverage stood at 3.2x.

Capital expenditure totaled EUR 19.5m in the third quarter of 2018
and EUR 45.1m in the first three quarters of the year. This included
the expansion of inhaler production in the USA, additions to the
product portfolio and enlargement of production capacity. In the
glass business, further capital expenditure related to the scheduled
furnace overhaul in the USA as well as to modernization measures,
tooling and molds.

Outlook

Gerresheimer's expectations for the financial year 2018, in each
case assuming constant exchange rates and excluding acquisitions and
divestments, remain as set out in the following. Exchange rates are
calculated on the basis of actual average exchange rates in the
financial year 2017. The largest exchange rate impact on the Group's
non-currency-adjusted earnings relates to the US dollar, for which
Gerresheimer has assumed an exchange rate of USD 1.12 per EUR 1.00.
The Brazilian and Indian currencies could also have greater relevance
should they further depreciate. In addition, both the energy price
trend-which is currently to Gerresheimer's disadvantage-and the
temporary impact of higher prices for plastic granules can also
result in fluctuations. The scheduled furnace overhaul at the Chicago
plant commencing in September 2018 was not yet completed on
publication of the third-quarter report and can likewise result in
minor variations in earnings performance for the fourth quarter.

- Gerresheimer continues to expect revenues at constant exchange
rates, excluding the Advanced Technologies Division, to be between
approximately EUR 1.38bn and EUR 1.4bn in the financial year 2018.
- For adjusted EBITDA at constant exchange rates, excluding the
Advanced Technologies Division, Gerresheimer continues to project a
range of around EUR 305m to EUR 315m, compared with EUR 307.2m
excluding the effect of fair value measurement of the Triveni put
option in the financial year 2017. In order to attain delivery
capability with regard to the recently awarded large-scale European
inhalers order as early as the fourth quarter of 2020, the aim is
to already secure construction of the necessary production building
and the conversion of existing capacity as quickly as possible in
2018. For this reason, adjusted EBITDA-depending on the progress of
necessary development work for the large projects-may tend toward
approximately EUR 305m.
- Capital expenditure in 2018 will amount to around 8% of revenues at
constant exchange rates.
- The results of the new Advanced Technologies Division need to be
added to the above.

Gerresheimer's long-term target for the entire Group, including
the new Advanced Technologies Division, remains as follows:

- Despite the acquisition of Sensile Medical, the Gx ROCE forecast
remains unaltered at approximately 15%.
- Due to the acquisition of Sensile Medical and the associated
purchase price payment, adjusted EBITDA leverage is expected to
increase above 3x on a temporary basis. The Company nonetheless
continues to consider leverage of about 2.5x to be right, with
temporary variation above or below this tolerated because M&A
activity cannot be planned in exact detail.

The initial, preliminary indications given in the second quarter
of 2018 with regard to the Group's long-term performance continue to
apply, as does the information on the acquisition of Sensile Medical,
which comprises the major part of the new Advanced Technologies
Division. Gerresheimer plans to add further detail to the initial,
preliminary indications for the years ahead with regard to the Group
as a whole, including the new Advanced Technologies Division, in the
guidance provided on publication of the Annual Report 2018 in
February 2019.

The full quarterly report is available here:

http://www.gerresheimer.com/en/investor-relations/reports

ots Originaltext: Gerresheimer AG
Im Internet recherchierbar: http://www.presseportal.de

Contact:

http://www.presseportal.de/nr/9072/dokument?langid=2
Media Contact:
Gerresheimer AG
Klaus-Bungert-Strasse 4
40468 Düsseldorf
Germany

Jens Kürten
Group Senior Director Communication & Marketing
Telephone: +49-211-6181-250
Telefax: +49-211-6181-241
E-Mail: j.kuerten@gerresheimer.com

Internet: http://www.gerresheimer.com

Original-Content von: Gerresheimer AG, übermittelt durch news aktuell